Reduction of nasal volume after allergen-induced rhinitis in patients treated with rupatadine: A randomized, cross-over, double-blind, placebo-controlled study

Journal of Investigational Allergology and Clinical Immunology

Volumn 19, Issue 6, 2009, Pages 488-493

  Valero, Antonio ^a,b,c   Serrano, C ^d   Bartra J ^a,b,c   Izquierdo, I ^e   Munoz Cano R ^a,b,c   Mullol, J ^b,c,f   Picado, C ^a,b,c  

^a HOSPITAL CLÍNIC   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c Global Allergy and Asthma European Network (GA2LEN)   (Spain)

^d FUNDACIÓN VALLE DEL LILI   (Colombia)

^e Clinical Development Unit   (Spain)

^f INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

Author keywords

Acoustic rhinometry; Nasal allergen challenge; Nasal obstruction; Rupatadine

Indexed keywords

ALLERGEN; NITRIC OXIDE; PLACEBO; RUPATADINE;

ADULT; ALLERGIC RHINITIS; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG TOLERABILITY; FEMALE; HUMAN; MALE; NASAL PRURITUS; NOSE OBSTRUCTION; RANDOMIZED CONTROLLED TRIAL; RHINOMETRY; RHINORRHEA; SNEEZING;

ADMINISTRATION, INTRANASAL; ADOLESCENT; ADULT; ANTI-ALLERGIC AGENTS; CYPROHEPTADINE; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; NASAL CAVITY; NASAL OBSTRUCTION; PRURITUS; RHINITIS, ALLERGIC, PERENNIAL; RHINITIS, ALLERGIC, SEASONAL; RHINOMETRY, ACOUSTIC; TREATMENT OUTCOME;

EID: 74849100332     PISSN: 10189068     EISSN: 16980808     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Nathan RA, Eccles R, Howarth PH, Steinsvåg SK, Togias A. Objective monitoring of nasal patency and nasal physiology in rhinitis. J Allergy Clin Immunol. 2005;115 (Suppl 1):S442-59.
2. Hilberg O, Pedersen OF. Acoustic rhinometry: recommendations for technical specifications and standard operating procedures. Rhinology. 2000;Suppl 16:3-17.
3. Struben VMD, Wieringa MH, Feenstra L, de Jongste JC. Nasal nitric oxide and nasal allergy. Allergy. 2006;61:665-70.
4. Serrano C, Valero A, Picado C. Nasal nitric oxide. Arch Bronconeumol. 2004;40:222-30.
5. Merlos M, Giral M, Balsa D, Ferrando R, Queralt M, Puigdemont A, García Rafanell J, Forn J. Rupatadine, a new potent, orally active dual antagonist of histamine and platelet-activating factor (PAF). J Pharmacol Exp Ther. 1997;280:114-21.
6. Queralt M, Merlos M, Giral M, Puigdemont A. Dual effect of rupatadine on enema induced by PAF and histamine in dogs: comparison with antihistaminas anf PAF antagonists. Drug Develop Res. 1996;39:12-8.
7. Keam SJ, Plosker GL. Rupatadine: A review of its use in the management of allergic disorders. Drugs. 2007:67:457-74
8. Picado C. Rupatadine: pharmacological profile and its use in the treatment of allergic disorders. Expert Opin. Pharmacother. 2006;7:1989-2001.
9. Fantin S, Maspero J, Bisbal C, Agache I, Donado E, Borja J, Molá O, Izquierdo I. A 12-week placebo-controlled study of rupatadine 10 mg once daily compared with cetirizine 10 mg once daily, in the treatment of persistent allergic rhinitis. Allergy. 2008;63:924-31.
10. Bousquet J, Khaltaev N, Cruz AA, Denburg J, Fokkens WJ, Togias A, Zuberbier T, Baena-Cagnani CE, Canonica GW, van Weel C, Agache I, Aït-Khaled N, Bachert C, Blaiss MS, Bonini S, Boulet LP, Bousquet PJ, Camargos P, Carlsen KH, Chen Y, Custovic A, Dahl R, Demoly P, Douagui H, Durham SR, van Wijk RG, Kalayci O, Kaliner MA, Kim YY, Kowalski ML, Kuna P, Le LT, Lemiere C, Li J, Lockey RF, Mavale-Manuel S, Meltzer EO, Mohammad Y, Mullol J, Naclerio R, O'Hehir RE, Ohta K, Ouedraogo S, Palkonen S, Papadopoulos N, Passalacqua G, Pawankar R, Popov TA, Rabe KF, Rosado-Pinto J, Scadding GK, Simons FE, Toskala E, Valovirta E, van Cauwenberge P, Wang DY, Wickman M, Yawn BP, Yorgancioglu A, Yusuf OM, Zar H, Annesi-Maesano I, Bateman ED, Ben Kheder A, Boakye DA, Bouchard J, Burney P, Busse WW, Chan-Yeung M, Chavannes NH, Chuchalin A, Dolen WK, Emuzyte R, Grouse L, Humbert M, Jackson C, Johnston SL, Keith PK, Kemp JP, Klossek JM, Larenas-Linnemann D, Lipworth B, Malo JL, Marshall GD, Naspitz C, Nekam K, Niggemann B, Nizankowska-Mogilnicka E, Okamoto Y, Orru MP, Potter P, Price D, Stoloff SW, Vandenplas O, Viegi G, Williams D. ARIA Update. Allergy. 2008;63(Suppl. 86):8-160.
11. ATS/ERS. Recommendations for standardized procedures for the online and offline measurement of exhaled lower respiratory nitric oxide. Am J Respir Crit Care Med. 2005;171:912-30.
12. Melillo G, Bonini S, Cocco G, Davies RJ, de Monchy JGR, Frolund L, Pelikan Z. Standardisation of nasal provocation tests. Allergy. 1997;52 Suppl 35:26-32
13. Mullol J, Bousquet J, Bachert C, Canonica WG, Gimenez-Arnau A, Kowalski ML, Martí-Guadaño E, Maurer M, Picado C, Scadding G, Van Cauwenberge P. Rupatadine in allergic rhinitis and chronic urticaria. Allergy. 2008;63 Suppl 87:5-28.
14. Stuebner P, Horak F, Zieglmayer R, Arnáiz E, Leuratti C, Pérez I, Izquierdo I. Effects of rupatadine vs placebo on allergen-induced symptoms in patients exposed to aeroallergens in the Vienna Challenge Chamber. Ann Allergy Asthma Immunol. 2006;96:37-44.
15. Kharitonov SA, Rajakulasingam K, O'Connor B, Durham SR, Barnes PJ. Nasal nitric oxide is increased in patients with asthma and allergic rhinitis and may be modulated by nasal glucocorticoids. J Allergy Clin Immunol. 1997;99:58-64.
16. Maniscalco M, Sofia M, Faraone S, Carratu L. The effect of platelet-activating factor (PAF) on nasal airway resistance in healthy subjects is not mediated by nitric oxide. Allergy. 2000;55:757-61.
17. Colantonio D, Brouillette L, Parikh A, Scadding GK. Paradoxical low nasal nitric oxide in nasal polyposis. Clin Exp Allergy. 2002;32(5):698-701.